Aetna

Does Aetna cover Zepbound?

Quick answer · Weight Loss

Aetna covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered with requirements. BMI of 35 or higher
  • ACA Marketplace: Covered with requirements. BMI of 35 or higher

Last verified June 2, 2026. Policy effective April 10, 2026. Source: policy-260.html. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What Aetna requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 35 or higher
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult weight loss - initial approval

All of:

  • Age 18 years or older
  • Baseline BMI >= 35 kg/m2
  • Participated in comprehensive weight management program (behavioral modification, reduced-calorie diet, increased physical activity) with continuing follow-up for at least 6 months prior to drug therapy
  • Used with reduced-calorie diet AND increased physical activity

Documentation to bring

  • Baseline BMI documentation (>= 35 kg/m2)
  • Documentation of participation in a comprehensive weight management program for at least 6 months prior to drug therapy

Quantity limits

  • 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL — 2 mL (4 pre-filled single-dose pens) / 21 days; 6 mL (12 pre-filled single-dose pens) / 63 days (84-day)

Approval and renewal

  • Initial approval: 8 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, Patient must have completed at least 3 months of therapy at a stable maintenance dose AND lost at least 5% of baseline body weight OR maintained initial 5% weight loss, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Zepbound vials and Zepbound Kwikpens are covered under the LillyDirect manufacturer program and not under this policy

Policy note: Policy groups Zepbound and Mounjaro as 'tirzepatide (Zepbound/Mounjaro)' for both OSA and weight loss criteria. The quantity limits table lists 'tirzepatide (Zepbound/Mounjaro) pre-filled single-dose pens' for all strengths from 2.5 mg to 15 mg. Zepbound vials and Kwikpens are excluded from this policy and covered under LillyDirect program.

Policy effective April 10, 2026 · verified June 2, 2026 · source: policy-260.html

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 35 or higher
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult weight loss - initial approval

All of:

  • Age 18 years or older
  • Baseline BMI >= 35 kg/m2
  • Participated in comprehensive weight management program (behavioral modification, reduced-calorie diet, increased physical activity) with continuing follow-up for at least 6 months prior to drug therapy
  • Used with reduced-calorie diet AND increased physical activity

Documentation to bring

  • Baseline BMI documentation (>= 35 kg/m2)
  • Documentation of participation in a comprehensive weight management program for at least 6 months prior to drug therapy

Quantity limits

  • 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL — 2 mL (4 pre-filled single-dose pens) / 21 days; 6 mL (12 pre-filled single-dose pens) / 63 days (84-day)

Approval and renewal

  • Initial approval: 8 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, Patient must have completed at least 3 months of therapy at a stable maintenance dose AND lost at least 5% of baseline body weight OR maintained initial 5% weight loss, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Zepbound vials and Zepbound Kwikpens are covered under the LillyDirect manufacturer program and not under this policy

Policy note: Policy groups Zepbound and Mounjaro as 'tirzepatide (Zepbound/Mounjaro)' for both OSA and weight loss criteria. The quantity limits table lists 'tirzepatide (Zepbound/Mounjaro) pre-filled single-dose pens' for all strengths from 2.5 mg to 15 mg. Zepbound vials and Kwikpens are excluded from this policy and covered under LillyDirect program.

Policy effective April 10, 2026 · verified June 2, 2026 · source: policy-260.html

Zepbound for Osa

What Aetna requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Moderate to severe OSA with obesity - initial approval

All of:

  • Request is for tirzepatide (Zepbound/Mounjaro)
  • Established diagnosis of moderate to severe OSA with AHI >= 15 events/hour on PSG or HSAT with technically adequate device
  • Current BMI >= 30 kg/m2
  • Used with reduced-calorie diet AND increased physical activity

Documentation to bring

  • Documentation of moderate to severe OSA diagnosis with AHI >= 15 events/hour on PSG or HSAT with technically adequate device
  • Current BMI documentation (>= 30 kg/m2)

Quantity limits

  • 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL — 2 mL (4 pre-filled single-dose pens) / 21 days; 6 mL (12 pre-filled single-dose pens) / 63 days (84-day)

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for Positive response to treatment from baseline evidenced by a decrease in OSA symptoms. Patient must be treated with maintenance dosage based on individual treatment response and tolerability. AHI documentation is re-required at continuation.

Not covered when

  • Zepbound vials and Zepbound Kwikpens are covered under the LillyDirect manufacturer program and not under this policy
  • No PAP/CPAP trial required prior to approval

Policy note: Policy uses 'current BMI >= 30' (not baseline) for OSA indication. No PAP/CPAP prior therapy requirement stated. OSA must be moderate to severe (AHI >= 15 events/hour). Policy refers to tirzepatide as 'Zepbound/Mounjaro' jointly for OSA criteria, though Mounjaro is not FDA-approved for OSA — Mounjaro is FDA-approved only for T2DM. The OSA criteria section header says 'Tirzepatide (Zepbound/Mounjaro) ONLY' suggesting Mounjaro could be approved for this off-label use under this policy.

Policy effective April 10, 2026 · verified June 2, 2026 · source: policy-260.html

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Moderate to severe OSA with obesity - initial approval

All of:

  • Request is for tirzepatide (Zepbound/Mounjaro)
  • Established diagnosis of moderate to severe OSA with AHI >= 15 events/hour on PSG or HSAT with technically adequate device
  • Current BMI >= 30 kg/m2
  • Used with reduced-calorie diet AND increased physical activity

Documentation to bring

  • Documentation of moderate to severe OSA diagnosis with AHI >= 15 events/hour on PSG or HSAT with technically adequate device
  • Current BMI documentation (>= 30 kg/m2)

Quantity limits

  • 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL — 2 mL (4 pre-filled single-dose pens) / 21 days; 6 mL (12 pre-filled single-dose pens) / 63 days (84-day)

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for Positive response to treatment from baseline evidenced by a decrease in OSA symptoms. Patient must be treated with maintenance dosage based on individual treatment response and tolerability. AHI documentation is re-required at continuation.

Not covered when

  • Zepbound vials and Zepbound Kwikpens are covered under the LillyDirect manufacturer program and not under this policy
  • No PAP/CPAP trial required prior to approval

Policy note: Policy uses 'current BMI >= 30' (not baseline) for OSA indication. No PAP/CPAP prior therapy requirement stated. OSA must be moderate to severe (AHI >= 15 events/hour). Policy refers to tirzepatide as 'Zepbound/Mounjaro' jointly for OSA criteria, though Mounjaro is not FDA-approved for OSA — Mounjaro is FDA-approved only for T2DM. The OSA criteria section header says 'Tirzepatide (Zepbound/Mounjaro) ONLY' suggesting Mounjaro could be approved for this off-label use under this policy.

Policy effective April 10, 2026 · verified June 2, 2026 · source: policy-260.html

Why Zepbound requests get denied by Aetna

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. No documented diet and exercise program.
  4. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does Aetna cover Zepbound?
Aetna covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
What BMI do you need for Zepbound under Aetna?
For weight loss on Employer / Commercial Insurance plans, Aetna requires a BMI of 35 or higher. Other plan types may differ — see each plan type below.
How long does a Zepbound approval last with Aetna?
Initial approvals last 8 months, and renewals are granted in 12-month periods.
What does Aetna require to renew Zepbound?
At least 5% weight loss from the starting weight, Patient must have completed at least 3 months of therapy at a stable maintenance dose AND lost at least 5% of baseline body weight OR maintained initial 5% weight loss, and at least 12 weeks on therapy before the first renewal.
How current is this information?
This page reflects Aetna's written policy as of April 10, 2026, last verified against the source document on June 2, 2026.

Other medications under Aetna

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes Aetna's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.